Dr. Aran is an Assistant Professor of Medical Diagnostics and Therapeutics at Keck Graduate Institute, a member of the Claremont Colleges, visiting faculty at the University of California Berkeley, and is Co-Founder of Nanosens Innovations and Cardea Bio. Dr, Aran also serves as a Consultant of Drug Delivery and Medical Diagnostics for the Bill and Melinda Gates Foundation. She received her undergraduate degree in electrical engineering from the City University of New York in 2007 and her Ph.D. in biomedical engineering from Rutgers University in 2012. She then continued her postdoctoral studies in bioengineering at the University of California Berkeley and was a recipient of the National Institutes of Health (NIH) postdoctoral training fellowship at the Buck Institute for Aging Research in 2015. Her research efforts focus on designing novel biosensing platforms, using 2D nanomaterials, for early disease diagnosis as well as understanding the biological processes that underlie aging. Her scientific vision is to explore the utility of nano-electronic systems to develop transformative and customizable biosensing platforms for pharmaceutical, clinical, and environmental applications.
Over the past few years, CRISPR has revolutionized the life sciences. Engineered to generate targeted DNA breaks, various DNA changes can be introduced in living organisms which offer the opportunity to treat a plethora of inherited diseases. The ongoing expansions of the CRISPR toolbox supports new applications across various domains of research and medicine. This session intends to provide an informative summary of latest breakthroughs with a focus on recent achievements and potential utility at the clinical setting. The discussion will also include challenges and needs to fully appreciate the potential of this technology.